Mannatech SEC Filings

Mannatech (MTEX) filed its Q3 2025 report, showing improved profitability despite softer sales. Net sales were $29.2 million, down 8.1% year over year, but gross margin improved to 76.4% as costs eased. Operating income rose to $2.0 million from $0.9 million. Other income benefited from foreign currency, contributing $0.6 million, and net income reached $1.9 million, or $1.01 per diluted share, versus a loss a year ago.

For the first nine months, net sales were $81.4 million, down 8.4%. The company reported a net loss of $3.9 million, or $2.06 per share, with a $2.6 million realized and unrealized foreign currency loss weighing on results. Cash and cash equivalents were $7.1 million as of September 30, 2025, compared with $11.4 million at year-end, and operating cash flow for the period was negative $2.7 million. Notes payable totaled $2.9 million at a 16% rate, with maturities extended to March 31, 2027.

Asia/Pacific led Q3 with 64.4% of sales, followed by the Americas at 27.1% and EMEA at 8.5%. Shares outstanding were 1,900,930 as of November 4, 2025. Inventory was $11.1 million and deferred revenue tied to loyalty programs ended at $2.3 million.

James Clavijo, Chief Financial Officer and director of Mannatech Inc. (MTEX), filed an amended Form 4 to report a grant of 10,000 stock options on 06/03/2025. The options carry an exercise price of $10.60 and an expiration date of 06/03/2035. The amendment corrects the vesting schedule: one-third vests on each anniversary of the grant over three years, with all options vesting immediately upon a change in control. After the reported transaction, Mr. Clavijo directly beneficially owns 14,500 shares. The amendment was filed because the original Form 4 misstated the vesting schedule.

Erin Barta Kemmler, General Counsel of Mannatech Inc. (MTEX), reported a correction to a previously filed Form 4 and disclosed recent equity activity. The reporting person disposed of 3,000 shares of common stock and was granted 10,000 stock options with an exercise price of $10.60 that convert into 10,000 common shares. After these transactions the reporting person directly beneficially owned 19,000 shares in total.

The amendment clarifies the options' vesting schedule: one-third vests on each anniversary of the grant over three years, with immediate vesting upon a change in control. The Form identifies the transaction date as 06/03/2025 and notes the original filing contained an incorrect vesting schedule.

Mannatech Inc. (MTEX) reporting person Fredrick Landen Granvel, President and CEO, amended a Form 4 to correct the vesting schedule for a stock option grant dated 06/03/2025. The amendment states the options (20,000 shares underlying) have a three-year vesting schedule: one-third on each anniversary of the grant, with immediate vesting upon a change in control. The options have a $10.60 exercise price and expire 06/03/2035. The report also shows a sale of 3,975 shares of common stock and a total beneficial ownership of 44,000 shares following the transactions. The amendment corrects an earlier filing that contained an incorrect vesting schedule.

Mannatech, Inc. filed a Current Report on Form 8-K dated August 12, 2025, stating that it issued a press release on May 13, 2025 announcing financial and operating results for the quarter ended June 30, 2025.

The filing furnishes that press release as Exhibit 99.1, titled "Mannatech Reports Financial Results for Second Quarter 2025". The 8-K lists the company's Nasdaq trading symbol MTEX and is signed by Chief Executive Officer Landen Fredrick. The 8-K text itself does not include numerical financial results; investors should review Exhibit 99.1 for the full figures.

Mannatech, Inc. reported consolidated net sales of $25.7 million for the three months ended June 30, 2025, down 7.4% from $27.7 million a year earlier; six-month sales were $52.2 million, down 8.6% from $57.1 million. Management attributes the revenue decline principally to weakened economic conditions in certain regions.

The company recorded a net loss of $4.3 million for Q2 2025 (loss per diluted share $2.27) versus a $0.6 million loss in Q2 2024; for the six months it reported a $5.8 million loss compared with six‑month net income of $0.6 million in 2024. A $2.7 million net foreign currency translation loss materially affected results. Cash and cash equivalents totaled $5.525 million (cash plus restricted cash $6.685 million) at June 30, 2025, down from $12.515 million at the period start. Inventories increased to $12.6 million; total assets were $32.8 million and shareholders' equity was $5.964 million at period end.